We claim:

1.

A method of providing an aqueous solution comprising a single chain variable region fragment at a concentration of at least 25 mg/mL, comprising: concentrating a first aqueous solution comprising said single chain variable region fragment at a concentration of less than 25 mg/mL, and containing at least about 3.5% (v/v) of a cosmotrope, by removal of solvent, to provide a second aqueous solution comprising a single chain variable region fragment at a concentration of at least 25 mg/mL.

2.	The method of claim 1 wherein the cosmotrope is a polyhydric alcohol.

3.	The method of claim 2 wherein the polyhydric alcohol is selected from the group consisting of glycerol, adonitol, erythritol, arabitol, sorbitol, mannitol, and xylitol.

4.	The method of claim 3 wherein the polyhydric alcohol is glycerol.

5.	The method of claim 1 wherein the cosmotrope is an amino acid or a methylamino acid.

6.	The method of claim 5 wherein the amino acid or methylamino acid is selected from the group consisting of ßalanine, tyaminobutync acid, proline, glycine betaine, taurine, carnitine, dimethylglycine, and sarcosine.

7.	The method of claim 1 wherein the cosmotrope is a sugar selected from the group consisting of sucrose, mannose, and trehalose.

8.	The method of claim 4 wherein the solvent contains between about 5% and about 20% glycerol (v/v).

9.	The method of claim 1 wherein said concentrating step is performed by ultrafiltration of said first aqueous solution.

10.	The method of claim 9 wherein said concentrating step comprises centrifugation of said first aqueous solution in a device comprising an ultrafiltration membrane, whereby said second aqueous solution is separated from a portion of solvent contained in said first aqueous solution.

11.	The method of claim 1 wherein said concentrating step is performed by osmotic force.

12.	The method of claim 1 wherein said single chain variable region fragment is covalently or noncovalently associated with a therapeutic, prophylactic, diagnostic, or imaging moiety.

13.	The method of claim 1 wherein said single chain variable region fragment is concentrated to at least 50 mg/mL.

14.	The method of claim 1 wherein said single chain variable region fragment is concentrated to at least 75 mg/mL.

15.	The method of claim 1 wherein the cosmotrope is glycerol present at from about 5% to about 10% v/v.

16.	The method of claim 12 wherein said single chain variable region fragment specifically binds to a ligand, whereby the targeting element confers apical to basolateral transcytosis to the therapeutic, prophylactic, diagnostic, or imaging moiety in an in vitro transcytotic assay.

17.

The method of claim 16, wherein the ligand is selected from the group consisting of : pIgR, pIgR stalk, transferrin receptor, apotransferrin, holotransferrin, vitamin B12 receptor, FcRn, an integrin, Flt1, Flk1, Flt4, a gpilinked protein, a scavenger receptor, folate receptor, and low density lipoprotein receptor.

18.	The method of claim 17, wherein the ligand is the pIgR stalk.

19.	The method of claim 17, wherein the targeting element binds a nonsecretory component region of pIgR.

20.	The method of claim 12 wherein said single chain variable region fragment is a fusion protein with a second polypeptide.

21.	The method of claim 20 wherein the second polypeptide is a cytokine.

22.	The method of claim 20 wherein the second polypeptide is an interferon.

23.	The method of claim 20 wherein the second polypeptide is an interleukin.

24.	The method of claim 20 wherein said single chain variable region fragment is concentrated to a concentration of at least 50 mg/mL of protein.

25.	The method of claim 20 wherein said single chain variable region fragment is concentrated to a concentration of at least 75 mg/mL of protein.

26.	A composition comprising said single chain variable region fragment at a concentration of at least 25 mg/mL, and a cosmotrope at at least 3.5% v/v.

27.	The composition of claim 26 wherein the cosmotrope is a polyhydric alcohol selected from the group consisting of glycerol, adonitol, erythritol, arabitol, sorbitol, mannitol, and xylitol.

28.	The composition of claim 27 wherein the polyhydric alcohol is glycerol.

29.	The composition of claim 26 wherein the cosmotrope is an amino acid or a methylamino acid selected from the group consisting of : ßalanine, yaminobutyric acid, proline, glycine betaine, taurine, carnitine, dimethylglycine, and sarcosine.

30.	The composition of claim 26 wherein the cosmotrope is selected from the group consisting of sucrose, mannose, and trehalose.

31.	The composition of claim 26 wherein said single chain variable region fragment is covalently or noncovalently associated with a therapeutic, prophylactic, diagnostic, or imaging moiety.

32.	The composition of claim 31 wherein said single chain variable region fragment is at a concentration of at least 75 mg/mL.

33.	The composition of claim 26 wherein the cosmotrope is glycerol.

34.	The composition of claim 33 wherein said single chain variable region fragment is at a concentration of at least 50 mg/mL.

35.	The composition of claim 34 wherein said single chain variable region fragment is at a concentration of at least 75 mg/mL.

36.	The composition of claim 26 wherein said single chain variable region fragment is a fusion protein with a second polypeptide.

37.	The composition of claim 37 wherein the second polypeptide is a cytokine.

38.	The composition of claim 37 wherein the second polypeptide is an interferon.

39.	The composition of claim 37 wherein the second polypeptide is an interleukin.

40.	The composition of claim 26 wherein said single chain variable region fragment specifically binds to a ligand, whereby the targeting element confers apical to basolateral transcytosis to the therapeutic, prophylactic, diagnostic, or imaging moiety in an in vitro transcytotic assay.

41.

The composition of claim 26, wherein the ligand is selected from the group consisting of : pIgR, pIgR stalk, transferrin receptor, apotransferrin, holotransferrin, vitamin B 12 receptor, FcRn, an integrin, Flt1, Flk1, Flt4, a gpilinked protein, a scavenger receptor, folate receptor, and low density lipoprotein receptor.

42.	The composition of claim 41, wherein the ligand is the pIgR stalk.

43.	The composition of claim 42, wherein the targeting element binds a non secretory component region of pIgR.

44.	The method of claim 1, firther comprising diluting the second aqueous solution to provide a third aqueous solution comprising a single chain variable region fragment at a reduced concentration.

45.	A kit for adminsiterung a formulation through an oronasopharyngeal route comprising: a formulation comprising a single chain variable region fragment at a concentration of at least 25 mg/mL; and an inhaler; contained within an enclosure.

46.	The kit of claim 45 wherein wherein said single chain variable region fragment is covalently or noncovalently associated with a therapeutic, prophylactic, diagnostic, or imaging moiety.

47.	The kit of claim 45 wherein said single chain variable region fragment is at a concentration of at least 75 mg/mL.

48.

A method of administering a biologically active compound to a patient comprising : administering to the patient via a pulmonary or oronasopharyngeal route a formulation comprising a biologically active compound linked to a single chain variable region fragment; wherein the formulation comprises at least 3.5% of a cosmotrope (v/v) and the single chain variable region fragment is at a concentration of at least 25 mg/mL, or wherein the formulation comprises at least 2% of a cosmotrope (v/v) and the formulation is obtained by dilution of a single chain variable region fragment solution at a concentration of at least 25 mg/mL.

49.	The method of claim 48 wherein the cosmotrope is a polyhydric alcohol.

50.	The method of claim 49 wherein the polyhydric alcohol is selected from the group consisting of : glycerol, adonitol, erythritol, arabitol, sorbitol, mannitol, and xylitol.

51.	The method of claim 50 wherein the polyhydric alcohol is glycerol.

52.	The method of claim 48 wherein the cosmotrope is an amino acid or a methylamino acid.

53.	The method of claim 52 wherein the amino acid or methylamino acid is selected from the group consisting of : ßalanine,aminobutyric acid, proline, glycine betaine, taurine, carnitine, dimethylglycine, and sarcosine.

54.	The method of claim 48 wherein the cosmotrope is a sugar selected from the group consisting of sucrose, mannose, and trehalose.

55.	The method of claim 48 wherein said single chain variable region fragment is at least 50 mg/mL.

56.	The method of claim 55 wherein said single chain variable region fragment is least 75 mg/mL, and the glycerol is present at a concentration of about 5% to about 10% (v/v).

57.	The method of claim 55 wherein said single chain variable region fragment is covalently or noncovalently associated with a therapeutic, prophylactic, diagnostic, or imaging moiety.

58.	The method of claim 57 wherein said single chain variable region fragment specifically binds to a ligand, whereby the targeting element confers apical to basolateral transcytosis to the therapeutic, prophylactic, diagnostic, or imaging moiety in an in vitro transcytotic assay.

59.

The method of claim 58, wherein the ligand is selected from the group consisting of : pIgR, pIgR stalk, transferrin receptor, apotransferrin, holotransferrin, vitamin B12 receptor, FcRn, an integrin, Fltl, Flk1, Flt4, a gpilinked protein, a scavenger receptor, folate receptor, and low density lipoprotein receptor.

60.	The method of claim 59, wherein the ligand is the pIgR stalk.

61.	The method of claim 60, wherein the targeting element binds a nonsecretory component region of pIgR.

62.	The method of claim 58 wherein said single chain variable region fragment is a fusion protein with a second polypeptide.